Evercore ISI Lowers McKesson (MCK) Target, Adds to Tactical Underperform List

McKesson Corporation (NYSE:MCK) is included among the 15 Cash-Rich Dividend Stocks to Invest in Right Now.

Evercore ISI Lowers McKesson (MCK) Target, Adds to Tactical Underperform List

On April 8, Evercore ISI lowered its price recommendation on McKesson Corporation (NYSE:MCK) to $950 from $1,000. It reiterated an Outperform rating on the shares. The changes came as part of its Q1 preview for healthcare technology and distribution, along with updates to its Tactical call lists. As part of those moves, the firm also added McKesson to its “Tactical Underperform” list.

A couple of days earlier, on April 6, BofA analyst Allen Lutz reduced his price target to $1,000 from $1,040 while maintaining a Buy rating. He pointed to the rapid decline in cash-pay GLP-1 prices as a key factor. He said the shift toward cash-pay prescriptions for Wegovy and Zepbound could weigh on McKesson’s FY27 EBIT outlook in its Prescription Technology Solutions segment. In his view, this trend may cause results to come in below Street expectations.

McKesson Corporation (NYSE:MCK) operates as a diversified healthcare services company focused on improving patient outcomes. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs, along with other healthcare-related products across the United States.

While we acknowledge the risk and potential of MCK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MCK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 NASDAQ Stocks with Highest Dividends and 15 Best Cheap Dividend Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.